FDA to review "missing" drug company documents

FDA to review “missing” drug company documents Fri, 31 Dec 2004 Related Link: Peter Breggin, MD RE: Eli Lilly’s Contentions that the BMJ Prozac Documents were Never Missing and Have No Significance In the final hours of 2004, an investigative reporter for . . . Continue reading →

How Did the Vioxx Debacle Happen? USA Today / Lancet

How Did the Vioxx Debacle Happen? USA Today / Lancet Tue, 12 Oct 2004 Dr. Eric Topol of the Cleveland Clinic: “The senior executives at Merck and the leadership at the FDA share responsibility for not having taken appropriate action and not . . . Continue reading →

AHRP in the News

Alliance for Human Research Protection in the Press Feb 17, 2005: FDA Critics Slam Plan for Safety Reform – Nature “This is smoke and mirrors and musical chairs,” says Vera Sharav, president of the New York-based Alliance for Human Research Protection. “They . . . Continue reading →

Antidepressant warnings make experts nervous

http://www.mysanantonio.com/news/metro/stories/MYSA020305.13A.antidepressants.6d572159.htm Antidepressant warnings make experts nervous Web Posted: 02/03/2005 12:00 AM CST Marina Pisano San Antonio Express-News Even as warning labels about the risk of suicidality in children and teens taking antidepressants are going on medication labels, a new study is showing . . . Continue reading →

Dr. Wolpe’s Accusations and Dr. Healy’s Response

Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this . . . Continue reading →

Columbine shooting victim sues Solvay Pharma – Insight

September 3, 2002 Columbine shooting victim sues Solvay Pharmaceuticals – Insight Magazine FYI Insight Magazine reporter, Kelly Patricia O’Meara, reports in (below) that 19- year old Mark Taylor, a victim of the shooting spree at Columbine high school in 1999, spent nearly . . . Continue reading →